Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

Inclusion Criteria:

- Must have given written informed consent (signed and dated) and any authorizations
required by local law.

- Willing to be confined to CRU for the entire duration required by the protocol.

- Male or female, between 18 and 80 years of age.

- Healthy subject with normal liver function must be non-smoker and no use of other
tobacco or nicotine-containing products. Subject with HI must be non-smoker, or smoke
≤10 cigarettes per day during the study.

- Healthy subject must not be taking any prescribed or non-prescribed medications unless
permitted. Subject with HI will be allowed to take their chronic medications unless
excluded by the protocol.

Exclusion Criteria:

- Pregnant or lactating women.

- Treatment with another investigational drug or device within 30 days prior to study
drug administration.

- Has donated or lost a significant volume of blood within 56 days or plasma within 7
days prior to Check-in day.

- Inability to swallow medication.

- Positive test for drugs of abuse and/or positive alcohol test at Screening or Day -1.

- Positive test at Screening for HBsAg, hepatitis C virus (HCV), or HIV.